NLS Pharmaceutics Ltd (NLSP)
0.1556
0.00 (0.00%)
USD |
NASDAQ |
May 22, 14:22
NLS Pharmaceutics Cash from Operations (TTM): -9.684M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -9.684M |
| June 30, 2023 | -13.51M |
| December 31, 2022 | -13.88M |
| June 30, 2022 | -12.87M |
| December 31, 2021 | -14.94M |
| June 30, 2021 | -9.930M |
| Date | Value |
|---|---|
| December 31, 2020 | -0.7294M |
| June 30, 2020 | -1.436M |
| December 31, 2019 | -0.19M |
| June 30, 2019 | -0.3311M |
| December 31, 2018 | -2.733M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-14.94M
Minimum
Dec 2021
-0.19M
Maximum
Dec 2019
-7.750M
Average
-9.807M
Median
Cash from Operations (TTM) Benchmarks
| AC Immune SA | -47.96M |
| CRISPR Therapeutics AG | -159.42M |
| Addex Therapeutics Ltd | -8.901M |
| Molecular Partners AG | -67.36M |
| MoonLake Immunotherapeutics | -48.70M |